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Synopsis: The Smn2B/- mice, a mouse model with reduced level of SMN protein, represent a good 
model of microvesicular steatohepatitis. They offer a reliable, low-cost early onset model to 
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Background & aims 
Non-alcoholic fatty liver disease is considered a health epidemic with potential devastating effects 
on the patients and the healthcare systems. Current pre-clinical models of NAFLD are invariably 
imperfect and generally take a long time to develop. A mouse model of SMN depletion (Smn2B/- 
mice) was recently shown to develop significant hepatic steatosis in less than 2 weeks from birth. 
The rapid onset of fatty liver in Smn2B/- mice provides an opportunity to identify molecular markers 
of non-alcoholic fatty liver disease (NAFLD). Here, we investigated whether Smn2B/- mice display 
typical features of NAFLD/non-alcoholic steatohepatitis (NASH). 
 
Methods 




The Smn2B/- mice develop microvesicular steatohepatitis within two weeks, a feature prevented by 
AAV9-SMN gene therapy. Although fibrosis is not overtly apparent in histological sections of the 
liver, there is molecular evidence of fibrogenesis and presence of stellate cell activation. The 
consequent liver damage arises from mitochondrial reactive oxygen species production and results 
in hepatic dysfunction in protein output, complement, coagulation, iron homeostasis, and IGF-1 
metabolism. The NAFLD phenotype is likely due to non-esterified fatty acid (NEFA) overload 
from peripheral lipolysis subsequent to hyperglucagonemia compounded by reduced muscle use 
and insulin resistance. Despite the low hepatic mitochondrial content, isolated mitochondria show 
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enhanced β-oxidation, likely as a compensatory response, resulting in the production of reactive 
oxygen species. In contrast to typical NAFLD/NASH, the Smn2B/- mice lose weight due to their 
associated neurological condition (Spinal Muscular Atrophy) and develop hypoglycemia.  
 
Conclusion 
The Smn2B/- mice represent a good model of microvesicular steatohepatitis. Like other models, it 
is not representative of the complete NAFLD/NASH spectrum. Nevertheless, it offers a reliable, 
low-cost, early onset model that is not dependent on diet to identify molecular players in NAFLD 
pathogenesis and can serve as one of the very few models of microvesicular steatohepatitis for 
both adult and pediatric populations. 
 




Non-alcoholic fatty liver disease is a significant burden on population health. At this time, it is 
estimated to affect the lives of nearly one billion individuals worldwide [1]. As many as 33% of 
Americans and 10% of children are thought to have the condition [1, 2]. NAFLD is often associated 
with other ailments including insulin resistance and type 2 diabetes mellitus (T2DM), visceral 
obesity, hypertension as well as dyslipidemia (often referred to as the metabolic syndrome), 
leading to compounding co-morbidities. Indeed, NALFD is associated with shortened survival [3, 
4]. Amongst NAFLD patients, ''liver disease’’ is the third most common cause of death (13%) in 
comparison to the general population where it sits at the 13th position and accounts for less than 
1% of deaths [3, 4]. 
 
NAFLD is characterized by increased storage of fatty acids in more than 5% of hepatocytes in the 
absence of alcohol use [1, 5]. It presents as a spectrum of severity that encompasses simple 
steatosis, steatohepatitis, cirrhosis and hepatocellular carcinoma [6]. Simple steatosis, which is the 
accumulation of hepatic fat with minimal consequences, is most commonly seen. However, a 
proportion of NAFLD patients will go on to develop inflammation of the liver, termed 
steatohepatitis or NASH, which can be complicated by fibrosis, cirrhosis and ultimately 
hepatocellular carcinoma [3, 7]. Despite NAFLD evolving as a major life impairing entity, 
effective pharmacological options to treat the disease are sparse [8]. This is in part due to the 
complex nature of NAFLD pathogenesis, which may involve multiple organ systems, including 
peripheral adipose tissue, the gut and potentially other metabolic organs [6, 9]. While simple 
steatosis appears to be a consequence of an imbalance of fatty acid input (lipogenesis, import) and 
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output (fatty acid oxidation, export) in the liver [10], it is currently hypothesized that “multiple 
hits” are required to develop NASH and more severe phenotypes [6].  
 
Multiple mouse models of NAFLD exist and offer great insight into molecular signaling events. 
However, in the context of the NAFLD research landscape, these models remain invariably 
imperfect in modelling the true phenotype of patients with NAFLD/NASH [6, 10-12]. Most mouse 
models do not typically display all the stages of NAFLD (simple steatosis, NASH, cirrhosis, 
hepatocellular carcinoma). Furthermore, there are many dietary models that hope to replicate the 
humanistic dietary components inducing associated conditions such as obesity, T2DM, and 
NAFLD. Unfortunately, the dietary approach generally necessitates months for the development 
of the desired phenotype, with consequent high cost of the food required, colony maintenance, 
space, and experimental interventions, leading to low cost-effectiveness of these models. For 
example, the western-style diet (or fast-food diet) can take as much as 6 months to lead to the 
development of NASH [9, 13]. On the other hand, the Methionine- and Choline-Deficient diet 
(MCD) leads to a much faster NASH phenotype (~2-8 weeks), yet the pathogenic mechanisms 
lack the systemic features of the human presentation marked by the metabolic syndrome [14, 15]. 
Monogenic models have also found a place in the NAFLD arena. The ob/ob and db/db mouse 
models lead to leptin pathway disruption with subsequent hyperphagia, obesity, diabetes and 
steatosis [6]. However, they lack the inflammatory process and progression to NASH unless a 
second insult occurs [6, 16]. Moreover, single gene models are considered a reductionist approach 
to the pathogenesis of NAFLD [9]. While these represent only a few examples of all available 
models, very few, if any, offer a rapid onset of NAFLD/NASH, which would allow for efficient 




The Smn2B/- mouse model was initially created to model a neurological condition called Spinal 
Muscular Atrophy (SMA). It contains a three-base pair substitution in the Survival motor neuron 
(Smn) gene, leading to alternative splicing of exon 7 [17], while the other allele is a knock-out 
allele. The Smn2B allele leads to a rapidly degraded truncated Smn protein in the majority of the 
case, while full-length Smn protein production occurs about 15% of the time [17-19]. The SMN 
protein was first identified to play a key role in pre-mRNA splicing [20-22]. SMN is also involved 
in a number of additional key cellular pathways, most pertaining to RNA metabolism (reviewed 
in [21, 23]). As such, SMN depletion has far-reaching effects on the transcriptome and cellular 
functions in all cells type of the body. Phenotypically, the Smn2B/- mouse model shows loss of 
motor neurons, neuromuscular junction abnormalities, skeletal muscle atrophy, muscle weakness, 
weight loss and a shortened lifespan of 25 days [18]. In addition, within the span of two weeks 
after birth, the Smn2B/- mouse displayed rapid onset of fatty liver disease and dyslipidemia while 
exposed to a normal chow diet [24]. Smn2B/- mice could offer a new model of NAFLD/NASH with 
a rapid disease onset without the need of long-term diet regimen for new molecular insights in 
NAFLD/NASH pathogenesis.  
 
In a comprehensive analysis of the metabolic defects in Smn2B/- mice, we here show development 
of NAFLD, and more specifically steatohepatitis with molecular evidence of induction of a 
fibrogenic process without established fibrosis, in a very short time span (less than 2 weeks [24]). 
The NAFLD in Smn2B/- mice was prevented by AAV9-SMN mediated gene therapy. Ultimately, 
the metabolic defects in Smn2B/- mice lead to a significant functional impairment in general protein 
production, complement protein expression, coagulation protein expression, and insulin-like 
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growth factor 1 (IGF-1) and iron homeostasis pathway regulation. The emergence of the NAFLD 
phenotype in Smn2B/- mice is likely from a dysfunctional pancreas-liver axis, insulin resistance, 
intrinsic hepatocyte defects and reduced muscle use caused by denervation. Despite showing many 
features of NAFLD, the Smn2B/- mice do not develop obesity, hyperinsulinemic hyperglycemia, or 
hepatic fibrosis. Altogether, the Smn2B/- mice will serve as one of the very few models of 
microvesicular steatohepatitis, for both adult and pediatric population. Like other models, the 
Smn2B/- mice are not representative of the complete NAFLD/NASH spectrum and features. 
Nevertheless, Smn2B/- mice offer a reliable, low-cost model to identify molecular players in the 






NAFLD in Smn2B/- mice develop steatohepatitis with molecular evidence of induction of the 
fibrogenic process  
We have previously identified microvesicular steatosis and dyslipidemia (elevated total 
cholesterol, very low density lipoprotein (VLDL), low density lipoprotein (LDL) and reduced high 
density lipoprotein (HDL)) in Smn2B/- mice, occurring in the span of a few days, typically between 
postnatal day (P) 9 and P13 [24]. Here we show that the microvesicular steatosis in Smn2B/- mice 
is directly due to Smn depletion as it can be completely prevented by gene therapy using 
intravenous injection of the scAAV9-CB-SMN vector (Fig 1A-D). It is important to note that 
levels of triglycerides and cholesterol esters were also restored to normal levels in the livers of 
treated Smn2B/- mice (Fig 1E,F). Next, we sought to investigate the severity, functional 
consequences and mechanisms underpinning the NAFLD in these mice. Plasma levels of serum 
transaminases alanine aminotransferase (ALT) and aspartate aminotransferase (AST), markers of 
liver damage, were mildly elevated in P19 Smn2B/- mice (Fig 1G,H). Muscular dystrophy patients 
can exhibit elevated serum transaminase levels, making skeletal muscle a potential source [25]. 
However, muscles from Smn2B/- mice are not degenerating [26], eliminating the possibility that 
they could be a source of transaminase. Plasma alkaline phosphatase (ALP) remained normal, but 
hepatic ALP staining was enhanced in livers from symptomatic Smn2B/- mice (data not shown). An 
active apoptotic process is apparent as indicated by increased transcript levels for multiple cell 
death genes such as Fas receptor (FasR), TNF receptor superfamily member 1A (TNFR1), BCL2 
associated X protein (Bax), and tumor protein p53 (p53) (Fig 1I), together with increased caspase 
3 staining in livers of P17-19 Smn2B/- mice (Fig 1K,L). The hepatic apoptosis appears to be p53-
dependent, as expression of classical targets of p53 [27], p21 and Mdm2, were strongly upregulated 
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(Fig 1J). We next performed a PCR gene array aimed to determine whether a fibrogenic process 
was active in Smn2B/- mice. We found that 36 of the 84 genes contained in the array showed a 1.5-
fold or greater change compared to WT (29 upregulated, 7 downregulated) (Fig 1M). Amongst the 
perturbed genes included those involved in the pro-fibrotic process, genes encoding ECM cell 
adhesion molecules, ECM remodeling enzymes, and TGFb superfamily members (Fig 1N). Of 
note, the induction of platelet derived growth factor (pdgfa and pdgfb), a change in ECM 
composition, and expression of integrins (itga2, itga3, itgb3, itgb8) are all signs of initiation of 
hepatic stellate cell activation, which would lead to fibrogenesis [28]. Moreover, the expression of 
transforming growth factor beta 2 (tgfbr2) and connective tissue growth factor (ctgf) are also 
considered strong fibrogenic stimuli [28]. Smooth muscle actin (acta2) was increased 2-fold, 
which can be indicative of activated hepatic stellate cells [29]. The strong induction of tissue 
inhibitor of metalloproteinase (Timp1) suggests an inhibition of endogenous ECM breakdown 
enzymes, which will likely exacerbate fibrosis [28]. Indeed, we observed the presence of enhanced 
alpha smooth muscle actin positive cells in the liver parenchyma of P19 Smn2B/- mice, indicating 
stellate cell activation (Fig 1O,P). We observed no hepatic neutrophil infiltration as neutrophils 
were mostly present in blood vessels rather than in the liver (data not shown). Finally, P17-19 
Smn2B/- mice did not display overt increase in collagen deposition (Fig 1Q-T). Overall, our analysis 
shows that Smn2B/- mice have steatohepatitis, hepatic cell death, and underlying molecular changes 
indicative of potential fibrogenesis, but without overt collagen deposition, perhaps due to the 
shortened lifespan of these mice. 
 
NAFLD in Smn2B/- mice leads to impairment of hepatic function 
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We next sought to identify whether liver damage in SMN depleted mice translated into functional 
sequelae using important and translatable clinical readouts. Total protein and albumin were 
reduced in the plasma of P19 Smn2B/- mice (Fig 2A,B). We identified a significant reduction in 
expression of many complement genes (Fig 2C) and altered transcript levels of genes involved in 
hemostasis in the liver of SMN depleted mice (Fig 2D). We also found transcripts for HNF4a, a 
transcription factor mediating synthetic capacity of the liver, to be reduced in Smn2B/- mice in a 
similar fashion to those with severe liver disease [30, 31] (Fig 2D). There was no difference in 
megakaryocyte or platelet number when staining for CD41 (data not shown). 
 
Iron metabolism and NAFLD have been suggested to be associated [32]. We also identified many 
dysregulated transcripts for genes involved in iron metabolism, including hepcidin, a gene 
producing hepcidin protein that acts as a master regulator of iron levels [33], as well as transferrin, 
heme oxygenase 1 and ceruloplasmin (Fig 2E). Accompanying these were concordant changes in 
protein levels of hepcidin and heme oxygenase but not transferrin (Fig 2F). Hepcidin was further 
shown to be decreased by immunohistochemistry (Fig 2G,H). Plasma iron levels trended lower 
(Fig 2I) but hepatic stores appeared unaffected in Smn2B/- animals (Fig 2J,K). We observed a trend 
towards higher levels of total bilirubin in the plasma of Smn2B/- mice (Fig 2L). This is likely due to 
the reduced efficacy of the hepatocytes to process bilirubin rather than blockage along the biliary 
tree. To test whether the molecular changes may affect iron dynamics and storage, the Smn2B/- mice 
were injected with iron dextran to observe uptake. Iron accumulation was more severe in the 
Smn2B/- livers upon iron loading, despite some variability seen in the Smn2B/- livers likely due to 
injection efficacy (Fig 2M-U). This is in line with reduced hepcidin expression, as hepcidin inhibits 
iron absorption in the gastrointestinal tract [33]. Our results are consistent with previous work 




Liver is also a key source of growth factors, including insulin-like growth factor 1 (IGF1). We 
identified an important reduction in Igf1 and insulin like growth factor binding protein acid labile 
subunit (Igfals) transcript levels, and an upregulation of insulin like growth factor 1 receptor (Igf1r) 
and insulin like growth factor binding protein 1 (Igfbp1) transcript levels (Fig 2V). A remarkable 
and progressive reduction of plasma IGF1 protein was observed over time in Smn2B/- mice (Fig 
2W). These data are consistent with previous reports in other SMN depleted mouse models [36-
38] and possibly NAFLD [39]. To test whether restoration of IGF-1 in Smn2B/- mice would 
attenuate the liver pathology, we performed IV injection of AAV9-hIGF1 at P1. However, we did 
not see any changes at the level of the hepatic TG content in AAV9-hIGF1 treated mice (data not 
shown). The level of endogenous mouse IGF1 was also not improved and human IGF1 was 
undetectable in the plasma (data not shown).  
 
Identification of molecular mechanisms underpinning NAFLD in Smn2B/- mice 
To identify alterations in specific molecular pathways that could render SMN depleted liver more 
susceptible to NAFLD, we undertook Tandem Mass Tagging (TMT) proteomic analysis of livers 
from pre-symptomatic P0 and P2 Smn2B/- mice compared to wild type, specifically to look for 
molecular changes present well before any overt pathology. We compartmentalized the data into 
biologically relevant subgroups based on the timing of altered protein abundance detection. This 
produced four subgroups, A, B, C and NS, where proteins in subgroup A (14% of the total IDs) 
represent those whose expression is already significantly altered at P0 but revert to wild type basal 
levels at P2. Subgroup NS (not altered at either P0 or P2) contained 65% of IDs (Fig 3A). We 
concluded that the proteins in these subgroups (A and NS) were therefore unlikely to be important 
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for the NAFLD phenotype in the Smn2B/- mice. Conversely, proteins in subgroup B (unchanged at 
P0, but significantly changed at P2) included 11% of total proteins, while subgroup C (altered at 
both P0 and P2) including 10% of total proteins were of more interest. Analysis of subgroup B 
using BioLayout Express3D and DAVID identified the mitochondrion cluster (increased protein 
expression) and the lipid metabolism cluster (decreased protein expression) (Fig 3B). A similar 
analysis of subgroup C identified clusters again associated with mitochondria (proteins 
significantly upregulated at both P0 and P2), extracellular signaling (proteins significantly 
decreased at both P0 and P2), and extracellular matrix proteins (significantly decreased at P0, 
however significantly increased at P2) (Fig 3C). To further refine potential pathways involved, we 
used ingenuity pathway analysis (IPA) software on proteins within subgroups B (Fig 3D,E) and C 
(Fig 3F). Of interest, the results from subgroup C revealed alterations in pathways related to 
“oxidative phosphorylation” (p = 6.35x10-3) and “mitochondrial dysfunction” (p = 1.11x10-2) (Fig 
3F). Furthermore, IPA analysis identified “metabolism” (p = 3.53x10-12) and “homeostasis of 
lipids” (p = 1.68x10-9) as some of the top functional subgroupings perturbed in Smn2B/- liver at P0 
(Fig 3G). Thus, this proteomic screen points towards mitochondrial dysfunction, a critical player 
in fatty acid clearance through β-oxidation. 
 
Assessment of mitochondrial number, anatomy and function in livers of Smn2B/- mice 
Given the proteomic data findings and the possibility that impaired mitochondrial function could 
be driving NAFLD/NASH in Smn2B/- mice, we focused on mitochondrial content, structure and 
function. Oxidative phosphorylation complex protein levels are largely unchanged at P9 in liver 
tissue homogenate. However, the protein expression of SDHB (complex II), MTCO1 (complex 
IV) and ATP5A (complex V) were reduced in tissue homogenate of P19 Smn2B/-livers (Fig 4A,B), 
20 
 
highlighting a potential depletion of mitochondrion number. A reduced mitochondrial density was 
confirmed by a lower activity of the citrate synthase enzyme at P19-21 (Fig 4C) [40]. Cursory 
ultrastructural analysis of mitochondria revealed no obvious gross alterations (Fig 4D-G). We 
wondered whether the potential mitochondrial depletion observed may be related to autophagy or 
mitophagy. Upon analysis of low magnification electron microscopy images, we observed 
numerous vacuoles containing breakdown material likely representing autophagic process in the 
P19 control livers (Fig 4 H,I). On the other hand, the P19 Smn2B/- livers showed propensity of fat 
globules that essentially overwhelmed most of the cells’ histology, making it difficult to discern 
any vacuoles within these cells (Fig 4J). However, there was a remarkable contrast in cells that 
appeared less affected in Smn2B/-livers, containing multiple vacuoles with cellular debris (Fig 4K). 
In accordance with the lack of vacuoles observed in affected cells, we identified an accumulation 
of P62 (also known as sequestosome 1), a protein targeting waste product to the autophagosome 
(Fig 4L). This can be in keeping with inhibition of autophagy [41]. Nevertheless, it remains 
difficult to draw conclusions whether abnormalities in the autophagic/mitophagic processes are at 
play. Given the overwhelming space occupied by the fat droplet, we wondered whether this may 
lead to endoplasmic reticulum stress, a feature that has been associated with NAFLD [42]. In fact, 
a potential link between ER stress and impaired autophagic flux has previously been established 
in the context of NAFLD [43]. There was only a mild induction of activation transcription factor 
4 (ATF4) but there was no clear induction of expression of other relevant ER stress proteins such 
Binding-Immunoglobulin protein (Bip), 94 KDa Glucose-regulated protein (GRP94), or C/EBP 




Next, we aimed to understand the functional capacity of the mitochondria in this setting. 
Surprisingly, high-resolution respirometry of isolated liver mitochondria from P19-21 Smn2B/- 
mice identified increased leak and ADP phosphorylation capacities when fueled by pyruvate, 
malate, and succinate (Fig 5A-E), or palmitoyl carnitine (data not shown). Interestingly, Smn2B/- 
mitochondrial function was similar to control mice at P9, a time point where hepatic fat 
accumulation is not readily observed [24]. Hepatic mitochondria from P9 and P19 Smn2B/- mice 
also exhibited an increase in reactive oxygen species (ROS) production (Fig 5F-J). It is possible 
that the increased capacity for respiration in isolated mitochondria from P19 Smn2B/- mice is a 
compensatory mechanism to restore metabolic homeostasis and/or in response to low 
mitochondrial density. In addition, the enhanced ROS production could be responsible in part for 
hepatocyte damage and death (Fig 1G-L). The increased capacity for fatty acid-supported 
respiration was consistent with the elevated levels of microsomal oxidation enzyme CYP4A (Fig 
5K,L), known to be active upon β-oxidation overload [6, 44, 45]. Carnitine palmitoyl transferase 
I (CPT1), an enzyme responsible for shuttling long chain fatty acid into the mitochondria for β-
oxidation, can be inhibited by malonyl-CoA, a product of de novo lipogenesis [45]. Such inhibition 
would lead to further fatty acid overspill in the microsomal oxidation pathway. We found CPT1 
to have reduced activity in comparison to both wild type and Smn2B/+ mice at P19 (Fig 5M). 
Overall, our results show that mitochondrial function of isolated mitochondria pathologically 
increased in the Smn2B/- mice, when oxidative processes are supported directly by substrates for 
complexes I and II, leading to ROS production. Given that CPT1 activity was decreased, it is 
possible that there is impaired formation of acyl carnitine species or inhibition of CPT1 activity, 
activation of proton leak and reduced uptake of long chain fatty acids for mitochondrial oxidation 
in vivo, further exacerbating hepatic steatosis.  
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Hormonal contribution to NAFLD in Smn2B/- mice 
Insulin insensitivity plays a major role in the development of NAFLD. Smn2B/- mice show 
abnormal glucose handling in intra-peritoneal glucose tolerance test [46]. Surprisingly, the Smn2B/- 
mice show sustained hypoglycemia with age in a normoinsulinemic state and a trend towards 
diminished C-peptide production at P19 (Fig 6A-C). Due to their small size and age, 
hyperinsulinemic clamp is not feasible to further assess insulin sensitivity. However, Smn2B/- mice 
show hepatic insulin resistance as demonstrated by lowered ability to phosphorylate protein kinase 
B (Akt) upon administration of insulin (Fig 6D,E). This may be related to the low IGF1 production 
by the liver [47]. Alternatively, we also noted a progressive elevation of plasma glucagon levels, 
which was first evident at P11 in Smn2B/- mice (Fig 6F). This increase in glucagon likely results 
from the increase in alpha-cell number in Smn2B/- pancreas [46] and/or low glucose. Glucagon 
signaling mediates some of its effects through the phosphorylation of Creb, which leads to 
expression of the gluconeogenic program [48]. We observed increased phospho-Creb levels in 
livers of P19 Smn2B/- mice (Fig 6G,H). Interestingly, there is a robust increase in the levels of GLP-
1 (Fig 6I), another byproduct of proglucagon, produced in the gastrointestinal tract. We further 
investigated adipocytic hormones (i.e. leptin, adiponectin), which are known to play a role in 
NAFLD/NASH progression and fibrosis [6]. We did not observe any changes in leptin or 
adiponectin in Smn2B/- mice (Fig 6J,K), which is in keeping with minimal evidence of fibrosis on 
histology in these mice. Other hormones from the gastrointestinal tract (ghrelin, GIP), pancreas 
(PP, amylin) and adipocyte (resistin) did not show a consistent pattern of misregulation, apart from 






Enhanced glucagon levels/signaling lead to glycogenolysis and gluconeogenesis in the liver, and 
lipolysis in the white adipose tissue to increase energetic substrate availability in the bloodstream 
[49]. Pathological glucagon signaling could lead to energy substrate overload in the blood, and 
subsequent stimulation of the liver to restore homeostasis via uptake of these substrates, including 
lipids. While limited change was identified in the time frame of acute fat accumulation in the liver 
on pathology (between P11-13 [24]) (Fig 8C-F), we observed eventual hepatic glycogen depletion 
at P19 (Fig 8A,B), a trend towards adipocyte size reduction (Fig 8G-M) and increased NEFA (Fig 
8N), a direct product of lipolysis, in the blood. These findings are consistent with enhanced 
glucagon signaling. More particularly, NEFA level was readily observable at P11 and worsened 
over time in comparison to control (Fig 8N). Triglyceride levels followed a similar progression, 
albeit in a delayed fashion (Fig 8O). Altogether, these findings point to a fatty substrate overload 






We systematically characterized typical features of NAFLD development in the Smn2B/- mice. The 
mice develop microvesicular steatohepatitis within two weeks of life, with increased serum 
markers of liver damage, hepatocyte cell death, molecular signs of fibrogenesis and hepatic stellate 
cell activation without established fibrosis. The Smn2B/- mice also display significant dyslipidemia 
(elevated total cholesterol, VLDL, LDL and reduced HDL) [24], peripheral lipolysis, functional 
hepatic deficits, alterations in mitochondrial function, evidence of involvement of alternative 
oxidative pathways and ROS production in the liver. All of these features have been observed in 
NAFLD [6]. Nevertheless, the Smn2B/- mouse as a model for NAFLD also has some limitations. 
(1) Although they show many molecular changes in genes involved in the fibrogenic process and 
hepatic stellate cell activation, they do not develop fibrosis, a component that is seen in NASH 
patients [6]. It is possible that they could go on to develop fibrosis after prolonged hepatic damage, 
however, their lifespan of 25 days [18] is likely too short to lead to a fibrotic phenotype. (2) Smn2B/- 
mice also lose weight due to their associated neurological condition. Interestingly, while NAFLD 
presentation often occurs in tandem with obesity, it also presents in individuals without weight 
gain [1]. Sedentary lifestyle (or immobility) is a risk factor for NAFLD [50], and exercise can 
sometimes prevent the NAFLD phenotype in preclinical models fed high-fat diet [51]. The lack of 
muscle use, whether from a pathogenic event (due to SMA) or by choice, may be necessary for 
adequate development of the phenotype. This is highlighted by the development of a mouse model 
with a sedentary lifestyle component such as the American Lifestyle-Induced Obesity Syndrome 
model (ALIOS) [52]. (3) Smn2B/- mice display low blood sugar and normal insulin levels but show 
evidence of insulin resistance. While most NAFLD patients have most components of the 
metabolic syndrome, which includes features of obesity, dyslipidemia, insulin resistance, 
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hyperglycemia, and hyperinsulinemia [6], we report that the Smn2B/- mice also show features of an 
incomplete metabolic syndrome phenotype (insulin resistance and dyslipidemia). 
 
In comparison, some popular NAFLD models also show limitations. For example, the methionine 
and choline deficient diet model does not exhibit any of the metabolic features [6, 10, 11, 14]. The 
ob/ob and db/db mutant mice, which display altered leptin signaling, have metabolic features but 
no inflammation or fibrosis [6, 10, 11]. The high fat diet appears to result in all features of the 
NAFLD spectrum, however, fibrosis is minimal and can take up to 36-50 weeks to develop [53]. 
As such, the Smn2B/- mice could provide an efficient mouse model of NAFLD due to its fast-onset 
steatosis phenotype, paired with the fact that no special and expensive diet is required, making it 
a cost-effective option. In fact, introduction of high fat diet did not drastically worsen the overall 
metabolic phenotype of the Smn2B/- mice [54], but studies were limited to biochemical measures. 
In addition, our study made use of both male and female mice, unlike other mouse models where 
males are predominantly used [55]. Needless to say, the Smn2B/- mice would allow for a different 
outlook on molecular players and organ system involvement in comparison to current available 
models of NAFLD. Indeed, the Smn2B/- mice could act as one of the few mouse models for pediatric 
NAFLD and/or microvesicular steatosis [55, 56]. To our knowledge, all current NAFLD models 
mostly display macrovesicular steatosis, apart from the Acox-/- mice, which develop predominantly 
microvesicular steatosis [57]. 
 
Despite not progressing to the most severe phenotype of cirrhosis, the functional analysis revealed 
significant changes at multiple levels. There was a reduction in total protein production, albumin 
production, complement expression, coagulation components, and IGF1 pathway members. These 
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changes are likely to represent a reduced synthetic potential of the damaged hepatocytes. In 
patients with failing liver, this low synthetic function can lead to a whole array of physical 
symptoms [58]. Interestingly, this is thought to be mediated by important hepatic transcription 
factors such as hepatic nuclear factor 4 alpha (HNF4a) in pre-clinical models [30] and human 
patients [31]. Many of the abnormal hepatic synthetic functions, but also the overall survival and 
phenotype, can be partially reversed by forced expression of HFN4a back into the organism [30]. 
We found HNF4a to be reduced in Smn2B/- mice in a similar fashion to those with severe liver 
disease. On the other hand, the etiology of IGF1 pathway and iron metabolism deficits are much 
less clear. IGF1 has been linked to liver disease in multiple studies, where its levels are generally 
observed to be low [39, 59]. Interestingly, IGF1 depletion may lead to insulin sensitivity [47, 60]. 
It is unclear whether IGF1 reduction is an initiator or a consequence of NAFLD. We suspect that 
the reduction of IGF1 is consequent of the reduced synthetic capacity and impaired stability of the 
remaining protein. The inability to form a stable complex of binding IGF1, IGFBP3, IGFals likely 
significantly impacts its degradation kinetics in light of the major difference in half-life bound to 
this complex vs. unbound (~10 min vs. 15 h respectively) [60, 61]. Iron status in NAFLD is also a 
notion that surfaced on many occasions. Iron is thought, with some conflicting evidence in humans, 
to potentially play a role in the development NAFLD [32]. However, the wealth of research tends 
to implicate iron in NAFLD when a surplus of iron or overload is present, with attempts to diminish 
iron load to improve the metabolic phenotype [32]. Our model rather presents with normal to low 
iron stores.  
 
Microvesicular steatosis is present in all Smn2B/- mice. It is only present in a minority (10%) of 
adult NAFLD patients and associated with more severe disease [5]. In the pediatric population, 
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microvesicular steatosis is generally clinically associated with inherited metabolic disorders and 
fatty acid oxidation defects [62]. We found no evidence of a β-oxidation deficit in our model using 
high resolution respirometry in isolated liver mitochondria. On the contrary, it appears that the 
isolated mitochondria have enhanced capacity, perhaps reflective of a compensatory reaction to 
the reduced mitochondrial density and the increase in triglyceride storage. Nevertheless, our 
proteomic screen identified alterations in two important clusters, namely mitochondria and lipid 
metabolism, close to birth, and well before any overt neurological or hepatic pathology develops. 
Interestingly, “mitochondrial pathway components” are often represented in “omic” data of SMN 
depleted tissue [63-68] and mitochondrial defects have previously been reported in cell culture and 
SMN depleted models [68-71]. Additionally, it is also part of NAFLD/NASH pathogenesis [6]. 
As such, additional investigation will be required to refine mitochondrial defects in this model and 
how it can relate to NAFLD/NASH.  
 
From our analysis, we conclude that NAFLD development in Smn2B/- mice is multifactorial. The 
proposed mechanism underpinning the defects is illustrated in Fig 9. We propose that the initial 
event leading to fatty acid dysregulation in the liver likely stems from abnormal glucose 
homeostasis. Hyperglucagonemia is induced early in Smn2B/- mice in response to low blood glucose 
in the bloodstream or from the pathological overpopulation of alpha cells in the pancreas [46]. 
Surprisingly, glucose levels in the Smn2B/- mice are reduced as early as P9. The glucose level 
remains low but is sustained, likely due to gluconeogenesis. Eventually, gluconeogenesis fails due 
to depleted glycogen storage in P19 Smn2B/- mice, leading to a sudden drop in glucose level in the 
blood [24]. Simultaneously, lipolysis of white adipose tissue, a by-product of glucagon signaling, 
is induced to ensure availability of energy substrate, represented by a progressive increase in 
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NEFA from P9 to P19 in Smn2B/- mice. This leads to increased fatty substrates in the bloodstream, 
which precede or coincide with muscle denervation. Skeletal muscle, a major consumer of energy 
substrates when innervated and fully functional, will have a diminished requirement for energy as 
denervation renders it non-functional in spinal muscular atrophy. As such, this leads to overload 
of fatty energy substrates in the circulation in a state of insulin resistance. Eventually, the 
susceptible liver will take up the lipid substrates for storage in an attempt to restore homeostasis, 
which in turn leads to liver steatosis. Pathological fat storage could spill over to the muscle 
compartment once the liver has reached saturation, which is consistent with our previous 
description of lipid droplets on ultrastructural analysis of skeletal muscle of Smn2B/- mice [72]. 
Finally, enhanced ROS production from mitochondrial oxidation leads to hepatic damage and 
functional deficits. From a molecular perspective, the link between SMN and NAFLD is not clear. 
SMN has an essential role in pre-mRNA splicing, amongst other housekeeping functions in the 
cells [23]. As such, SMN depletion has far-reaching effects on the transcriptome and cellular 
activity. Transcriptomic analysis of various SMN depleted tissue identified the liver to be the most 
abnormal [20]. The direct targets of SMN in the liver are unknown at this time. Additionally, SMN 
likely have be cell-specific consequences and intrinsic defects of cells from other metabolic organs 
may be at play. A comprehensive analysis of transcriptomic data of relevant metabolic tissues 
involved in NAFLD will be key in identifying player contributory to its phenotype.  
 
Altogether, Smn2B/- mice will provide an appropriate NAFLD model. It can be leveraged for high 
throughput identification of molecular pathways involved in NAFLD due to the fast onset of the 
phenotype (less than 2 weeks) and the lack of a required diet, making it a cost-effective option in 
the study of NAFLD pathogenesis.  
29 
 
Materials and Methods 
Study design 
We have recently identified the increased prevalence dyslipidemia and fatty liver [24] in SMA 
patients and SMA mouse models. This sparked a project with the following 2 pre-specified 
objectives: (1) Identify consequences of the fatty acid defect, (2) Identify the etiology of these 
defects and how it relates to NAFLD pathogenesis. As it pertains to this manuscript, the etiologies 
of the defects were suspected on prior experience with this SMA mouse model and NAFLD 
literature. It included denervation [24], liver-intrinsic defects, mitochondrion, and external factors 
(other organs). Serum analysis and lipid quantification were outsourced, and, thus, analyses were 
performed in a blinded fashion. N number are described in each figure legend. Statistical approach 
is as described below and in figure captions. Collaboration between laboratories of Kothary and 
Parson and colleagues occurred mid-project, given overlapping results that were converging. 
Hence, the resulting manuscript offers data that have been concordant in two independent 
laboratories (albeit using different experimental paradigms).  
 
Mouse models 
The Smn2B/- (wild type C57BL/6J background) [18] mouse lines were housed at the University of 
Ottawa Animal Facility and cared for according to the Canadian Council on Animal Care. 
Experimentation and breeding were performed under protocol OHRI-1948 and OHRI-1927. 
Smn+/- mice were crossed to Smn2B/2B mice to obtain Smn2B/+ and Smn2B/- animals. C57BL/6J wild 
type mice were bred separately. All experiments using mice in the UK were performed in 
accordance with the licensing procedures authorized by the UK Home Office (Animal Scientific 
Procedures Act 1986). All tissues in the Kothary laboratory were collected while mice were fed 
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ad libitum. Tissues undergoing biochemical analysis in the Kothary laboratory were collected 
between 9 and 11 AM to limit the effect of the circadian rhythm.  
 
Production and administration of scAAV9-CB-SMN or ssAAV9-hIGF1 
scAAV9-CB-SMN vectors were produced at the Bertarelli Platform for Gene Therapy in EPFL 
(Switzerland), using a construct similar to the one described in [73]. The self-complementary 
scAAV9-CB-SMN and ssAAV9-hIGF1 vector were produced by calcium phosphate transfection 
of HEK293-AAV cells (Agilent) with pAAV-CB-SMN [73] or pAAV-hIGF1 and pDF9 plasmids. 
Briefly, the vector was purified from the cell lysate using an iodixanol density gradient followed 
by anion exchange chromatography (HiTrap Q-FF column, GE Healthcare). The scAAV9-CB-
SMN or ssAAV9-hIGF1 vector was finally resuspended and concentrated in DPBS on a 
centrifugal filter unit (Amicon® Ultra-15, Millipore). The titer of the vector suspensions was 
determined by qPCR using an amplicon located in the inverted terminal repeats as described in 
[74]. The obtained titers of the scAAV9-CB-SMN vectors were 9.613 VG/mL and 3.013 VG/mL. 
The obtained titers of the AAV9-hIGF1 vectors was 1.514 VG/mL. Smn2B/- and Smn2B/+ mice were 
injected with 5 x 1010 VG of the AAV9-CB-SMN or AAV9-hIGF1 viral vector at P1 through the 
facial vein and the mice were then allowed to age until P19.  
 
Insulin sensitivity 
Protocol was performed as in [42] with slight modifications. Briefly, P19 wild-type and Smn2B/- 
mice were fasted for 4 hours. They subsequently received intraperitoneal injection of 2U/kg of 
insulin (Novolin ge Toronto 100 UI/ml, human) and were sacrificed 20 min later for tissue 
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collection. Livers were then collected for protein analysis and probed for pAKT, total AKT, and 
tubulin (see section on immunoblotting). 
 
Iron loading 
The protocol was carried out as previously published [75]. Briefly, P12 Smn2B/+ and Smn2B/- mice 
received intraperitoneal injection of 250 µg iron dextran (Sigma, cat# D8517) per g body weight. 
Seven days after injections, the mice were sacrificed for collection of the liver for histological 
analysis with Prussian blue (see section on Gross morphology, tissue processing and staining of 
animal tissues). 
 
Gross morphology, tissue processing and staining of animal tissues 
Livers and white adipose tissue were fixed in formalin (1:10 dilution buffered, from Protocol, cat 
#245-684) for 24-48 h or 72 h (white adipose tissue) at 4ºC and then transferred in 70% ethanol at 
4ºC until processing. All samples used for histological assessment were processed at the University 
of Ottawa (Department of Pathology and Laboratory Medicine) and embedded in wax using a 
LOGOS microwave hybrid tissue processor. Paraffin block tissues were cut with a microtome at 
3-4 µm thickness. Hematoxylin & eosin (H&E) staining was performed using a Leica autostainer 
XL. Periodic acid-Schiff (PAS), Prussian blue, oil red O and Sirius red staining were performed 
using standard methods. Staining for platelets, neutrophils, hepcidin were performed in the 
Kothary laboratory. Briefly, the paraffinized sections were deparaffinized in 3 changes of xylene 
substitute Histo-Clear (Fisher Scientific, 50-899-90147) for 10 min each followed by 2 changes in 
a 50/50 mixture of absolute ethanol and Histo-Clear for 3 min each. Sections were gradually 
rehydrated in 100%-95%-70%-50%-0% ethanol. A heat-induced antigen retrieval step was 
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performed when needed using Tris/EDTA buffer, pH 9.0 or sodium citrate buffer, pH 6.0. Sections 
were permeabilized with 0.1% Triton X-100 (Sigma) for 5 min and then blocked 1 h in blocking 
buffer (10% goat serum, 1% bovine serum albumin and 0.1% Triton X-100 in PBS). Slides were 
incubated with primary antibodies alone or in combination NIMP-R14 (Abcam ab2557, 1:100), 
Hepcidin-25 (Abcam ab75883, 1:250), CD-41 (Abcam ab225896, 1:100-250) and alpha smooth 
muscle actin (Abcam, ab7817, 1:250) diluted in a first dilution buffer (1%BSA, 0.1% triton x-100 
in PBS) for 90 min at room temperature. Sections were subsequently washed three times in PBS 
for 15 min, and then incubated with the secondary antibodies Alexa Fluor-488, Alexa Fluor-555 
(Invitrogen, 1:250) diluted in a second dilution buffer (10% goat serum, 0.01% triton x-100 in 
PBS) for 1 h at room temperature. Sections were washed in PBS for 5 min and counterstained with 
4’,6-diamidino-2-phenylindole, dihydrochloride (DAPI, Molecular Probes, D1306, 1:5000) for 5 
min. Slides were washed two times in PBS for 10 min and mounted with fluorescent mounting 
medium (DAKO mounting media). Pictures were acquired using microscope Zeiss Axio Imager 
M1 mounted with a digital camera. Tissue undergoing immunofluorescence for caspase3 and 
collagen IV were processed in Dr. Parson’s laboratory. The tissues for immunofluorescence 
staining were sectioned (5 μm) on a cryostat (Leica, CM3050 S) or a microtome (Leica, RM2125 
RTS). Liver sections were stained for caspase 3 (Abcam Ab13847 1:100) and collagen IV 
(Millipore AB756P 1:100). Antigen retrieval was performed to visualize Casp3. Briefly, air dried 
sections were quickly washed in PBS, then submerged into pre-warmed Antigen Retrieval Buffer 
and placed into water bath set at 90°C for 40 min (Caspase 3). The sections were removed from 
the bath but left submerged in the buffer allowing them to cool down but not dry out. After 
approximately 30 min, the slides were quickly washed in PBS and subjected to the traditional IHC 
staining protocol. Acquisition of signal was either obtained by slide scanning with a MIRAX MIDI 
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digital slide scanner (Zeiss) and images acquired using 3DHISTECH Panoramic Viewer 
1.15.4/CaseViewer 2.1/ZenBlue 3.2 or directly captured using a Nikon eclipse e400 microscope 
(x10, x20 or x40 objective) and its images captured using QICAM Fast 1394 camera and 
Improvision Velocity 4 image capture software. 
 
Total ALP in situ assay 
Liver sections on slides were washed in PBS twice for 5 min each, followed by three washes in 
NTMT (100 mM NaCl, 100 mM Tris-HCl pH 9.5, 50 mM MgCl2, and 1% Tween-20) for 10 min 
each. After incubation in color reaction solution (NTB, BCIP, and NTMT buffer), sections were 
washed in NTMT twice for 10 min each, followed by two washes in PBS for 10 min each. Sections 
were post-fixed in 4% PFA for 30 min, washed in PBS twice for 10 min each, and slides mounted 
in 90% glycerol.  
 
Gene expression studies and PCR array 
RNA from liver was extracted using Qiagen RNeasy Mini kit and reverse transcribed using RT2 
first strand kit according to manufacturer’s protocol. A complete list of primers is available in the 
supplementary material (Supplementary Table 1). A standard curve was performed for each primer 
set to ensure their efficiencies. Each QPCR reaction contained equal amount of cDNA, Evagreen 
SyBR (Biorad), RNase/DNase-free water and appropriate primers (100-200 nM or according to 
PrimePCR protocol) in a final volume of 25 μl or 20 μl (for primePCR primers). To confirm 
amplicon specificity, a melting curve analysis was performed. Two negative controls were 
included in every QPCR plate and consisted of water in lieu of cDNA. QPCR results were 
quantified using 2-∆∆Ct method. Results were normalized with 2 genes (mentioned in each figure 
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legend containing QPCR data) identified as appropriate stable internal reference given M value 
below 0.5 and coefficient of variance below 0.25. PCR arrays for mouse fibrosis were purchased 
at Qiagen (PAMM-120Z) and were performed according to the manufacturer’s protocol. Analysis 
was performed using their analysis platform (https://geneglobe.qiagen.com/us/analyze/). Genes 
for normalization were manually selected to identify minimal difference in geometric means and 
Gapdh, Actb and Hsp90ab1 were selected (Geometric mean 23.54 vs. 23.55 in control vs. Smn2B/-
). P-values were directly obtained from the analysis platform. 
 
Immunoblotting  
Total protein lysate was collected by homogenization of flash frozen liver in RIPA lysis buffer 
(Cell Signaling). Protein concentrations were determined using the Bradford assay (Bio-Rad) or 
BCA assay. Protein extracts were subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis and examined by immunoblot, as previously described [76] or with modified 
blocking conditions where Odyssey blocking buffer (Li-Cor 927-40000) replaced 5% milk 
depending on the method of acquisition (Enhanced Chemiluminescence or Odyssey acquisition). 
Primary antibodies used were as follows: pAKT (Ser473) (Cell Signaling, cat# 4060, 1:2000), 
AKT (Cell Signaling, cat #9272, 1:1000), Hepcidin (Abcam, cat# ab75883, 1:1000), Heme 
oxygenase (Abcam, cat# ab68477, 1:10 000)), P62, (Abcam, cat# ab56416, 1:1000), pCreb 
(Ser133) (Cell Signaling 9198, 1:1000), Creb (Cell Signaling 9104, 1:1000), MitoOxphos (Abcam, 
ab110413 - 1:250), alpha-tubulin (Abcam, ab4074 - 1:2500-5000 and Calbiochem, CP06 
1:10000), Cyp4A (Abcam, ab3573 - 1:1000), Cyp2E1 (Abcam, ab28146 - 1:2500). Secondary 
antibodies used were IRDye (Li-Cor) 680 or 800 (Li-Cor - 1:10000 to 1:20000) and antibodies for 
ECL were Goat anti-rabbit HRP (Bio-Rad, cat# 1721019, 1:5000). Signals were detected with 
35 
 
Odyssey CLx (Li-Cor) or by enhanced chemiluminescence (Pierce, cat# 32209). Results were 
normalized to total protein or tubulin. 
 
Transmission Electron Microscopy 
Electron microscopy was performed as previously described [72]. Briefly, P9 & P19 Smn2B/+ and 
Smn2B/- mice were anesthetized and then perfused transcardially with 5 ml of phosphate-buffered 
saline (PBS) followed by 10-20 ml of Karnovsky’s fixative (4% paraformaldehyde, 2% 
glutaraldehyde and 0.1 M sodium cacodylate in PBS, pH 7.4). Livers were collected and fixed 
overnight in the same fixative at 4°C. A liver segment of 1-2 mm length was collected from the 
same lobe of each mouse and processed for electron microscopy by a method previously described 
[71]. All specimens were observed under a transmission electron microscope (Hitachi 7100, Gatan 
digital camera) operated at voltage 75 kV. 
 
High-resolution respirometry and mitochondrial enzymatic assays 
These experiments were performed in Dr Harper’s laboratory. Livers were excised from P9 and 
P19-21 Smn2B/+ and Smn2B/- mice. Mitochondria were isolated using a slightly modified version 
from [77]. Briefly, livers were washed in IBC buffer (see protocol [77]) and then minced and 
resuspended into 3 (P19) or 2 ml (P9) of IBC buffer. Liver pieces were then transferred to a glass-
Teflon homogenizer for homogenization using electric rotator. The homogenates were then 
centrifuged at 800g for 10 min at 4ºC, supernatant was transferred to a new tube and centrifuged 
again 8600g 10 mins at 4ºC, where pellet was resuspended in half initial volume of IBC buffer. 
This process was repeated once. Mitochondria were indirectly quantified by Bradford assay. 700 
ug (P19-21) and 500 ug (P9) of mitochondria were then introduced in the high-resolution 
36 
 
respirometer (O2K; Oroboros, Austria) for respirometry measurements. The list and order of 
substrates and compounds introduced in the chamber for each protocol can be found in 
Supplementary Table 2 and 3. The substrates and compounds were added to the chamber after 
mitochondria reached steady state. Quantification was performed using the Oroboros software. 
 
Citrate synthase and CPT1 activity 
These experiments were performed in Dr. Harper’s laboratory. Enzyme activity for citrate synthase 
(CS) and CPT1 was determined as previously described with some modifications [78]. Briefly, 
tissue was weighed and homogenized in ice-cold homogenization buffer (25 mM TRIS-HCL 
pH7.8, 1 mM EDTA, 2 mM MgCL2, 50 mM KCL, 0.50% Triton X-100) using modified Dounce 
homogenization with a pestle attached to a rotor. Homogenates were centrifuged at 14,000 x g for 
10 min at 4oC, and the supernatant was collected. The assay was performed using the BioTek 
Synergy 96-well microplate reading spectrophotometer at room temperature. CS activity was 
determined by measuring absorbance at 412 nm in 50 mM Tris-HCl (pH 8.0) with 0.2 mM DTNB, 
0.1 mM acetyl-coA and 0.25 mM oxaloacetate. Rate of absorbance change, and path length of 
each well was determined using BioGen 5.0. The enzyme activities were calculated using the 
extinction factor, 13.6 mM-1cm-1 for CS. For CPT1 enzymatic assay. CPT1 activity was 
determined by measuring absorbance at 412 nm in 50 mM Tris-HCl pH8.0 with 0.2 mM DTNB 
in a buffer containing 150 mM KCl, 0.1 mM palmitoyl-CoA and 0.25 mM l-carnitine. Enzymatic 





Tissues were extracted and flash frozen. When required, tissues were pooled to obtain 100 mg. 
Tissue lipid analysis for quantification and profiles were performed at the Vanderbilt Mouse 
Metabolic Phenotyping Center. Briefly, lipids were extracted using the method of Folch-Lees [79]. 
The extracts were filtered, and lipids recovered in the chloroform phase. Individual lipid classes 
were separated by thin layer chromatography using Silica Gel 60 A plates developed in petroleum 
ether, ethyl ether, acetic acid (80:20:1) and visualized by rhodamine 6G. Phospholipids, 
diglycerides, triglycerides and cholesteryl esters were scraped from the plates and methylated 
using BF3/methanol as described in [80]. The methylated fatty acids were extracted and analyzed 
by gas chromatography. Gas chromatographic analyses were performed on an Agilent 7890A gas 
chromatograph equipped with flame ionization detectors, a capillary column (SP2380, 0.25 mm x 
30 m, 0.25 µm film, Supelco, Bellefonte, PA). Helium was used as a carrier gas. The oven 
temperature was programmed from 160ºC to 230ºC at 4ºC/min. Fatty acid methyl esters were 
identified by comparing the retention times to those of known standards. Inclusion of lipid 
standards with odd chain fatty acids permitted quantification of the amount of lipid in the sample. 
Dipentadecanoyl phosphatidylcholine (C15:0), diheptadecanoin (C17:0), trieicosenoin (C20:1), 
and cholesteryl eicosenoate (C20:1) were used as standards.  
 
Blood chemistry  
Blood was collected following decapitation of the mice and collection of the blood via capillary 
using Microcuvette CB 300 K2E coated with K2 EDTA (16.444.100). All the blood collected in 
this study was sampled randomly (i.e., no fasting period) between 9 and 11 am to limit the effect 
of the circadian rhythm. Mice were subsequently dissected as soon as possible to limit the effect 
of fasting. Samples were then spun at 2000 g for 5 min at room temperature to extract plasma. 
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Samples were pooled when large assay volume were required. Analysis of albumin, total protein, 
ALP, ALT, AST, bilirubin, iron, and NEFA (P19 only) were performed at the National Mouse 
Metabolic Phenotyping Center (MMPC) at the University of Massachusetts Medical School using 
a Cobas Clinical Chemistry Analyzer (Roche Diagnostics, Indianapolis, IN, USA) while plasma 
non-esterified fatty acid (NEFA) levels were measured photometrically using a kit (Zenbio, 
Durham, NC), according to the manufacturer’s protocol. Analysis of glucose, triglycerides and 
NEFA (P9-P13) was performed at Comparative Clinical Pathology Services, LLC., Columbia, 
Missouri, using commercially available assays on a Beckman-Coulter AU680 Automated Clinical 
Chemistry analyzer (Beckman-Coulter, Inc., Brea, CA). Triglyceride and glucose assays were 
obtained from Beckman-Coulter and the assay for non-essential Fatty Acids from Randox 
Laboratories (Randox Laboratories, Ltd., Kearneysville, West Virginia). In this study, we also 
used Luminex xMAP technology. The multiplexing analysis was performed using the Luminex™ 
100 system (Luminex, Austin, TX, USA) by Eve Technologies Corp. (Calgary, Alberta). Eleven 
markers were simultaneously measured in the samples using a MILLIPLEX Mouse 
Cytokine/Chemokine 11-plex kit (Millipore, St. Charles, MO, USA) according to the 
manufacturer’s protocol. The 11-plex consisted of Amylin (active), C-Peptide 2, GIP (total), GLP-
1 (active), ghrelin (active), glucagon, insulin, leptin, PP, PYY and Resistin. The assay sensitivities 
of these markers range from 1-23 pg/mL for the 11-plex. Individual analyte values are available 
in the MILLIPLEX protocol. IGF-1 was measured in the samples using a R&D Systems Mouse 1-
Plex Luminex Assay (R&D Systems, Minneapolis, MN, USA) according to the manufacturer’s 
protocol. The assay sensitivity of this marker is 3.46 pg/mL. Adiponectin was measured in the 
samples using MILLIPLEX Mouse Cytokine/Chemokine 1-plex kit (Millipore, St. Charles, MO, 
USA) according to the manufacturer’s protocol. The assay sensitivity of this marker is 3 pg/mL. 
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For experiments using Luminex system, if analytes were too low to be identified and outside of 
the dynamic range, it was deemed to be zero and reflected as such on dot plot graphs. 
 
Proteomic analysis 
Proteomic analysis was performed in Dr. Parson’s and Wishart’s laboratories. Protein extraction, 
peptide tandem mass tagging and fractionation were performed by the FingerPrints Proteomics 
facilities at the University of Dundee. Protein samples were thawed, and proteins were extracted 
from each sample using Tris-HCl buffer (100 mM, pH 8.5) containing 4% SDS and 100 mM DTT. 
Samples are then processed using FASP protocol [81] with some modifications. After, removal of 
SDS with 8 M urea, proteins were alkylated with iodoacetamide and filters were washed 3 times 
with 100 mM Tris-HCL pH 8 then twice with 100 mM triethyl ammonium bicarbonate (TEAB). 
Proteins on the filters are then digested twice at 30oC with trypsin (2 x 2 µg), first overnight and 
then for another 6h in a final volume of 200 µl. Resulting tryptic peptides were desalted using C18 
solid phase extraction cartridge (Empore, Agilent technologies) dried, dissolved in 100 mM TEAB 
and quantified using Pierce Quantitative Colorimetric Peptide Assay (Thermo Scientific). 100 µg 
of desalted tryptic peptides per sample were dissolved in 100 µl of 100 mM TEAB. The 10 
different tandem mass tag labels comprising the TMT10plex™ kit (Thermo Fisher Scientific) were 
dissolved in 41 µL anhydrous acetonitrile. Each dissolved label was added to a different sample. 
Samples were labelled as follows: Sample B – Tag 127N Liver from 3 WT mice at P0; Sample D 
– Tag 128N Liver from 3 Smn2B/- mice at P0; Sample G – Tag 129C Liver from 3 WT mice at P2; 
Sample I – Tag 130C Liver from 3 Smn2B/- mice at P2 (this was part of a wider proteomic screen, 
hence the discontinuous lettering). The sample-label mixture was incubated for 1 hour at room 
temperature. Labelling reaction was stopped by adding 8 µl of 5% hydroxylamine per sample. 
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Following labelling with TMT, samples were mixed, desalted, and dried in a speed-vac at 30°C. 
Samples were re-dissolved in 200 µl ammonium formate (NH₄HCO₂) (10 mM, pH 10) and 
peptides were fractionated using an Ultimate 3000 RP-High pH High Performance Liquid 
Chromatography column (Thermo-Scientific) containing an XBridge C18 column (XBridge 
peptide BEH, 130Å, 3.5 µm, 2.1 X 150 mm) (Waters, Ireland) with an XBridge guard column 
(XBridge, C18, 3.5 µm, 2.1 X 10 mm) (Waters, Ireland). Buffers A and B used for fractionation 
consist, respectively, of (A) 10 mM ammonium formate in milliQ water and (B) 10 mM 
ammonium formate with 90% acetonitrile. Before use, both buffers were adjusted to pH 10 with 
ammonia. Fractions were collected using a WPS-3000FC auto-sampler (Thermo-Scientific) at 1 
minute intervals. Column and guard column were equilibrated with 2% Buffer B for twenty 
minutes at a constant flow rate of 0.2 ml/min. 175 µl per sample was loaded onto the column at a 
rate of 0.2 ml/min, and the separation gradient was started 1 minute after sample was loaded onto 
the column. Peptides were eluted from the column with a gradient of 2% Buffer B to 5% Buffer B 
in 6 minutes, and then from 5% Buffer B to 60% Buffer B in 50 minutes. Column was washed for 
16 minutes in 100% Buffer B and equilibrated at 2% Buffer B for 20 minutes as mentioned 
previously. The fraction collection started 1 minute after injection and stopped after 80 minutes 
(total 80 fractions, 200 µl each). The total number of fractions concatenated was set to 15 and the 
content of the fractions was dried and suspended in 50 µl of 1% formic acid prior to analysis with 
LC-MS. 
  
LC-MS/MS Analysis  
Liquid chromatography-tandem mass spectrometry was performed by FingerPrints Proteomics 
Facilities at the University of Dundee, to the following protocol: Analysis of peptide readout was 
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performed on a Q Exactive™ HF Hybrid Quadrupole-Orbitrap™ Mass Spectrometer (Thermo 
Scientific) coupled with a Dionex Ultimate 3000 RS (Thermo Scientific). LC buffers were made 
up to the following: Buffer A (2% acetonitrile and 0.1% formic acid in Milli-Q water (v/v)) and 
Buffer B (80% acetonitrile and 0.08% formic acid in Milli-Q water (v/v). Aliquots of 15 µL per 
sample were loaded at a rate of 5 µL/min onto a trap column (100 μm × 2 cm, PepMap nanoViper 
C18 column, 5 μm, 100 Å, Thermo Scientific) which was equilibrated with 98% Buffer A. The 
trap column was washed for 6 minutes at the same flow rate and then the trap column was switched 
in-line with a resolving C18 column (Thermo Scientific) (75 μm × 50 cm, PepMap RSLC C18 
column, 2 μm, 100 Å). Peptides were eluted from the column at a constant flow rate of 300 nL/min 
with a linear gradient from 95% Buffer A to 40% Buffer B in 122 min, and then to 98% Buffer B 
by 132 min. The resolving column was then washed with 95% Buffer B for 15 min and re-
equilibrated in 98% Buffer A for 32 min. Q Exactive™ HF was used in data dependent mode. A 
scan cycle was comprised of a MS1 scan (m/z range from 335-1800, with a maximum ion injection 
time of 50 ms, a resolution of 120,000 and automatic gain control (AGC) value of 3x106) followed 
by 15 sequential-dependent MS2 scans (with an isolation window set to 0.4 Da, resolution at 
60,000, maximum ion injection time at 200 ms and AGC 1x105. To ensure mass accuracy, the 
mass spectrometer was calibrated on the first day that the runs were performed. 
  
Database search and protein identifications 
Raw MS data from the 15 fractions were searched against mouse (Mus musculus) protein 
sequences from UniProtKB/Swiss-Prot (Version 20160629) using the MASCOT search engine 
(Matrix Science, Version 2.4) through Proteome Discoverer™ software (Version 1.4.1.14, Thermo 
Fisher). Parameters for database search were as follows: MS1 Tolerance: 10ppm; MS2 Tolerance: 
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0.06da; fixed modification: Carbamidomethyl (C) Variable Modification: Oxidation (M), 
Dioxidation (M), Acetyl (N-term), Gln->pyro-Glu (N-term Q), TMT 10(N-term and K); maximum 
missed cleavage: 2; and target FDR 0.01. All identifications were quantified as relative ratios of 
expression compared to control (WT at P0) through Proteome Discoverer™ software (Thermo 
Fisher, Version detailed above). Relative ratios along with UnitProtKB/Swiss-Prot identifications 
were exported into Microsoft Excel as a raw data file for further in-silico analysis. 
  
In-Silico Analysis 
Mass spec data (from above) was manually subdivided into four distinct groups - Group A 
(changed at P0 but not at P2), B (changed at P0 and P2), C (not changed at P0, but changed at P2) 
and NS, depending on the protein expression changes at P0 and P2 with level of significance 
identified as expression change increased or decreased by 20%. This procedure allows proteins 
most likely to be involved in the development of pathology, namely those altered at P0 and P2 or 
P2 only (Groups B and C) to be identified. These subgroups were then uploaded into the BioLayout 
Express3D for expression profile clustering, DAVID functional annotation for enrichment analysis 
or Ingenuity Pathway analysis (IPA) for hierarchical cascade mapping and upstream regulator 
prediction. See below. 
  
BioLayoutExpress3D 
BioLayoutExpress3D [82] is a tool for visualization and clustering data. Routinely, proteomic data 
sets are uploaded to BioLayout Express3D, a Pearson’s correlation coefficient (r-value) is used to 
measure similarity between protein expression profiles and a threshold for the Pearson’s 
correlation coefficient is set. The data set is then visualized as nodes (proteins) that are connected 
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to each other in a network based on their expression levels (edges). This data set can further be 
subdivided into discreet “clusters” based on a Markov Clustering Algorithm (MCL), thus 
segregating data in an unbiased manner as previously described [83-85]. 
  
DAVID 
The Database for Annotation, Visualization and Integrated Discovery (DAVID) provides a widely 
accepted set of functional annotation tools to interrogate the molecular composition of data sets 
relative to known findings in the current literature [86, 87]. The functional clustering tool divides 
a list of proteins into functional protein groups, each with a different Enrichment Score (ES), thus 




Data are presented as the mean ± standard error of the mean. A two-sided Student’s t test was 
performed using Microsoft Excel or Graphpad Prism 7 to compare the means of data when only 
two groups were compared (i.e., wild type vs. Smn2B/-). One-way ANOVA analysis and two-way 
ANOVA were also used to distinguish differences between more than two groups when multiple 
comparisons were necessary (i.e., wild type vs. Smn2B/+ vs. Smn2B/-) or additional variables were 
present. The post-test used for the ANOVA was either Tukey or Sidak. Significance was set at P 
≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for ****. N number for each 
experiment is as indicated in the figure legends. 
 
Data and materials availability 
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All authors had access to the study data and had reviewed and approved the final manuscript. All 
data associated with this study are available in the main text or the supplementary materials. Raw 
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Fig. 1 Symptomatic Smn2B/- mice suffer from significant liver damage without fibrosis. (A-D) 
Microvesicular steatosis is evident (40X, H&E staining) at P19 effectively prevented by systemic 
AAV9-SMN injection at P1. (E-F) Levels of triglycerides and cholesterol esters were restored to 
normal levels in the liver of AAV9-SMN treated Smn2B/- mice. (G-H) Elevation of ALT and AST 
in the plasma of Smn2B/- mice at P19. (H-J) FasR, TNFR1, Bax, p53, as well as p53 transcriptional 
targets p21 and Mdm2 transcripts were significantly increased in the liver. (K-L) Increased caspase 
3 staining in P17 Smn2B/- livers (magnification 100X). (M) PCR array targeting fibrosis pathways 
revealed 36 of 84 genes to be significantly changed 1.5-fold or grater in Smn2B/- livers. The green 
horizontal line represent threshold for p = 0.05 while the vertical lines represent a change of 1.5-
fold. (N) Genes with more than 2-fold change were found in multiple categories of the fibrosis 
pathways. (O-P) Smooth muscle actin staining (63X) in the liver parenchyma in accordance with 
stellate cell activation (as shown with arrows) in Smn2B/- livers at P19. (Q-T) Representative images 
of Sirius red (magnification 40X) and collagen IV (magnification 200X) staining show no overt 
difference in hepatic fibrosis in P17-19 Smn2B/- mice. QPCR data were normalized with SDHA 
and PolJ (I-J). Scale bar represents (O-P) 10 µm, (Q-R) 20 µm, (A-D) 50 µm, and (K-L, S-T) 100 
µm. N value for each experiment is as follows: N = 10 for G-H, 4 for A-F, I-J, M-N, 3-4 for K-L, 
3 for O-P, 5 for Q-R, 4 for S-T. Statistical analysis were one-way ANOVA with Tukey’s multiple 
comparison test for E-F and unpaired two-sided Student’s t-test for G-J. P-values from the PCR 
array were obtained from the Qiagen analysis platform. P ≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 




Fig. 2 Liver functional deficits in multiple pathways in symptomatic Smn2B/- mice. (A,B) Low 
levels of total protein and albumin in plasma from P19 Smn2B/- mice. (C-D) Major alterations in 
levels of transcripts for complement, hemostasis in livers from P19 Smn2B/- mice. (E) Iron 
metabolism genes are misregulated, with (F) associated concordant changes at the protein level of 
hepcidin and heme oxygenase but not transferrin. (G-H) Immunostaining of hepcidin (63X) was 
also reduced. (I) Iron levels are reduced in plasma but unchanged in liver (Prussian blue staining, 
40X) (J-K). (L) A trend towards higher total bilirubin protein in the plasma in Smn2B/- mice. (M-
U) Iron loading showed more severe iron accumulation in the Smn2B/- livers. (V-W) Major 
alterations in the expression of IGF1 pathway components, leading to progressive depletion of 
IGF-1 hormone in the plasma from Smn2B/- mice. QPCR data were normalized with SDHA and 
PolJ (C, D, E, V). Scale bar represent 10 µm (G-H), 50 µm (J-K) and 200 µm (M-U). (N value for 
each experiment is as follows: N = 8-10 for A-B, I, L and W, 4-5 for C-E, F, , J-K, M-U and V, 3 
for G-H, unpaired two-sided Student’s t-test for all except for (W) Two-way ANOVA with Sidak’s 
multiple comparison test, P ≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for 
****) 
 
Fig. 3 Proteomic analysis of P0 and P2 Smn2B/- livers identifies mitochondrial and lipid 
metabolism as prominent perturbations. (A) Scatterplots showing protein expression ratios of 
Smn2B/- to P0 wild type (control) liver. A 20% threshold altered expression was applied. Left 
column of paired scatterplots shows Smn2B/- to wild type ratios for 7229 proteins at birth (P0) and 
P2. Group B identified by filtering for proteins altered only at P2 in Smn2B/- livers (P0 = ns (0.8 ≤ 
x ≤ 1.2) and P2 = p ≤ 0.05 (x < 0.8 or x > 1.2)). Group C filters for proteins altered at P0 and at P2 
in Smn2B/- (P0 and P2 = p ≤ 0.05 (x < 0.8 or x > 1.2). (B-C) Group B and Group C graphical 
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representation of Smn2B/- to wild type ratio proteins at P0 and P2, left graph prior to clustering, 
right graphic post application of the MCL clustering algorithm (inflation value 2.2) analyzing 
coordinately expressed proteins. These are represented as mean ratio-change per cluster. In cluster 
visualization the proteins are spheres with correlation between them of r ≥ 0.9 indicated by black 
lines. Each identified cluster has a functional annotation with n number stating how many proteins 
are present within the cluster. (D) IPA top canonical pathways highlighting the main disrupted 
cascades in Group B data set. Stacked bar chart displays the percentage of proteins that were 
upregulated (red), downregulated (green), and proteins that did not overlap with our data set 
(white) in each canonical pathway. The numerical value at the top of each bar represents the total 
number of proteins in the canonical pathway. (E) Top diseases and functions linked to our Group 
B data set identified by IPA functional analysis. (F) IPA top canonical pathways highlighting the 
main disrupted cascades in Group C data set at P0 (left) P2 (right). Stacked bar chart displays the 
percentage of proteins that were upregulated (red), downregulated (green), and proteins that did 
not overlap with our data set (white) in each canonical pathway. The numerical value at the top of 
each bar represents the total number of proteins in the canonical pathway. (G) Top diseases and 
functions linked to our Group C data set identified by IPA functional analysis. (see methods for 
comprehensive description of analysis) 
 
Fig. 4 Smn2B/- liver mitochondria show increased β-oxidation and ROS production. (A,B) 
Western blot analysis of subunits of the mitochondrial complexes shows no significant change 
prior to hepatic fat accumulation at P9 but shows significant down-regulation of CII, CIV and CV 
subunit proteins in P19 Smn2B/- liver homogenates. (C) Lower citrate synthase activity in livers of 
P19-21 Smn2B/- mice, suggests decreased mitochondrial density per mg of tissue. (D-G) 
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Mitochondrial structure appears relatively spared at both P9 and P19 in Smn2B/- livers. (H-K) 
Potential lower propensity of autophagic/mitophagic vacuoles in P19 Smn2B/- livers due to intense 
fatty infiltration, where less affected cells appear to retain some vacuoles. (L) P62 elevation in P19 
Smn2B/- livers, potentially contributing to autophagic blockade. Scale bar represents (D-G) 500 nm, 
(H,J) 6 µm, and (I,K) 2 µm. N value for each experiment is as follows: N = 3-4 for A-B, D-G and 
H-L, 5-9 for C, Two-way ANOVA with Sidak’s multiple comparison for A-B, two-way ANOVA 
with Tukey’s multiple comparison tests for C, two-sided Student’s t-test for L, P ≤ 0.05 for *, P ≤ 
0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for ****) 
 
Fig. 5 Smn2B/- liver mitochondria show increased β-oxidation and ROS production. (A-E) 
High resolution respirometry of Smn2B/- hepatic mitochondria shows increased leak and higher 
respiratory capacity at P19 but not at P9 in comparison to Smn2B/+ hepatic mitochondria. (F-J) 
Smn2B/- hepatic mitochondria had an increase in ROS production during most respiratory states in 
comparison to Smn2B/+ mitochondria. (K-L) Increased expression of CYP4A is evident in P19 
Smn2B/- livers. (M) Reduced CPT1 activity is present in livers of Smn2B/- mice compared to WT. (N 
value for each experiment is as follows: N = 4 for K-L, 6-9 for A-J, M, Two-way ANOVA with 
Sidak’s multiple comparison for all except M two-way ANOVA with Tukey’s multiple 
comparison tests. P ≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for ****) 
 
Fig. 6 Impaired insulin and glucagon pathways in Smn2B/- mice. (A) Plasma glucose was lower 
throughout P9 to P13 in Smn2B/- mice in comparison to wild type mice. (B) Insulin levels were 
relatively maintained throughout the Smn2B/- mice lifespan. (C) A trend towards diminished C-
Peptide production is only seen at P19 in Smn2B/- mice. (D-E) Insulin sensitivity is about half the 
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capacity of control animals as shown by reduced Akt phosphorylation (Ser473) in livers of P19 
Smn2B/- mice. (F) Progressive elevation of plasma glucagon occurs in Smn2B/- mice with a ~15-fold 
increase by P11. (G,H) Western blot analysis shows a 10-fold increase in phospho-Creb, a 
downstream molecular event of glucagon activation, in P19 Smn2B/- livers in comparison to WT. 
(I) Plasma GLP-1, a product of the cleavage of proglucagon, is altered in a similar fashion. (J-K) 
Adipokines leptin and adiponectin levels remained relatively unchanged. (N value for each 
experiment is as follows: N = 8-10 in A, K, 8-10 for P4, P11 and 4-6 at P19 in (B, C, F, I, J), 3 in 
D-E and 4 in G-H, Two-way ANOVA with Sidak’s multiple comparisons test for (A-C, F, I, J), 
one-way ANOVA with Tukey’s multiple comparison tests for D-E, unpaired two-sided student’s 
t-test for G, H, K, P ≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for ****). 
 
Fig. 7 Major metabolic hormone levels are largely unchanged in the plasma of Smn2B/- mice. 
(A-C) PYY is the only significantly changed hormone originating from the gastrointestinal system 
while ghrelin and GIP were largely unchanged. (D-E) Minor differences are present in pancreatic 
hormones. (H-J) No changes in resistin were observed were observed. (N value for each 
experiment is as follows: N = 8-10 for P4, P11 and 4-6 at P19 in A-F, two-way ANOVA with 
Sidak’s multiple comparisons test, P ≤ 0.05 for *, P ≤ 0.01 for **). 
 
Fig. 8 Hyperglucagonemia leads to increased substrate release in the plasma of Smn2B/- mice. 
(A-F) PAS stained liver sections (5X) at P19, P13 and P11 reveal glycogen depletion in P19 
Smn2B/- mice (A-B), but not at P13 (C-D) and P11 (E-F). (G-L) H&E sections (20X) of 
subcutaneous adipose tissue show a trend toward reduction in adipocyte size at P19 Smn2B/- mice 
(G,H,M) but not at P13 (I,J,M) and P11 (K-M). (N) Plasma NEFA progressively increase from P9 
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to P19, concordant with increased lipolysis of white adipose tissue. (O) Plasma triglyceride 
quantification showed a similar trend as NEFA, albeit in a delayed fashion. Scale bar represents 
500 µm in A-F and 100 µm in G-L. (N value for each experiment is as follows: N = 8-10 in N-O, 
5 for A-F, 5-10 for G-M, Two-way ANOVA with Sidak’s multiple comparisons test for (M, O); 
note that no statistical analysis were performed on (N) given results obtained through different 
techniques for P19, P ≤ 0.05 for *, P ≤ 0.01 for **, P ≤ 0.001 for *** and P ≤ 0.0001 for ****). 
 
Fig. 9 Schematic summarizing the findings of the present study. Undefined glucose/pancreatic 
abnormalities lead to hyperglucagonemia leading to hepatic glycogen breakdown and adipocyte 
lipolysis in the context of hepatic insulin resistance. This results in increased plasma energy 
substrate availability prior or concomitantly to muscle denervation, the major user of energy in the 
blood. This leads to overload of fatty substrates in the blood, which the liver takes up to restore 
homeostasis, leading to steatosis. To compensate and dispose the unnecessary lipids, 
mitochondrial oxidation is increased to burn excess lipids, which eventually becomes overloaded 
and requires alternative peroxisomal and microsomal oxidation pathway. Such a compensation 
leads to increased ROS production, liver damage, hepatocyte apoptosis and eventually functional 
impairment. The schematic art pieces used in this figure were provided by Servier Medical art 
https://smart.servier.com. Servier Medical Art by Servier is licensed under a Creative Commons 





Supplementary Table 1. Primers used in this study  
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Amplex	ultra	red 2	uL 10	mM 50	uM 
Horseradish	
peroxidase 
10	uL 10	mM 10	U/mL 
H2O2 5	ul 40	uM 0.1	uM	titrations	X3 
800	mM	Malate 5	uL 800	mM 2	mM 
Pyruvate 10	uL 2	M 5	mM 
ADP/Mg2+ 20	uL,	20	uL 500	mM 5	mM 
Glutamate 10	uL 2	M 10	mM 
Succinate 20	uL 1	M 10	mM 
500	mM	ADP/Mg 20	uL,	20	uL 500	mM 5	mM 




Antimycin	A 1	uL 5	mM 2.5	uM 















800	mM	Malate 5	uL 800	mM 2	mM 
Oct	Car 4	uL 100	mM 0.2	mM 
ADP/Mg2+ 20	uL,	20	uL 500	mM 5	mM 
Pyruvate 10	uL 2	M 5	mM 
Glutamate 10	uL 2	M 10	mM 
Succinate 20	uL 1	M 10	mM 
500	mM	ADP/Mg 20	uL,	20	uL 500	mM 5	mM 




Antimycin	A 1	uL 5	mM 2.5	uM 




Sodium	Azide 50	uL 4	M 100	mM 
 
